Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAgronomics Regulatory News (ANIC)

Share Price Information for Agronomics (ANIC)

Share Price is delayed by 15 minutes
Get Live Data
6.55    0.00 (0.00%)
Bid:
6.20
Ask:
6.90
Spread: 0.70 (11.29%)
Market Cap: £70.42m
ANIC Live PriceLast checked at - London Stock Exchange

Intraday Agronomics Share Chart

Edison issues flash on Agronomics (ANIC)

26 Sep 2022 08:48

RNS Number : 6052A
Agronomics Limited
26 September 2022
 

London, UK, 26 September 2022

 

Edison issues flash on Agronomics (ANIC)

Agronomics (ANIC) invests in cellular agriculture companies. In our last note, we discussed a shift in its focus more towards precision fermentation companies, whose development is more advanced, offering greater near-term commercial potential. This week's announcement that Onego Bio, one of ANIC's portfolio companies, has entered a partnership with Perfect Day, a US precision fermentation company, is a further step in this direction. The alliance should hasten Onegro Bio's route to market and financial viability and increase ANIC's potential to realise further NAV uplifts. Food giant Nestlé's recent move into precision fermentation is further evidence that ANIC's increasing interest in this sector may prove timely.

 

News of Onego Bio's alliance with Perfect Day closely follows another announcement that bodes well for the future of precision fermentation technology more generally, and for ANIC's increasing investment in this sector. Last week, Nestlé announced it is exploring emerging technologies for the development of animal-free dairy protein-based products. Nestlé's interest in fermentation technology demonstrates the attraction this technology has as a potentially viable method of producing animal-free protein at scale. Specifically, Nestlé will pilot a novel product that uses animal-free protein produced by Perfect Day. The product will be tested in the US market later this year. Further details about this product are not yet available, but its development will be supported by Nestlé's R&D Accelerator programme, which brings together start-ups, academic institutions and Nestlé scientists with the purpose of accelerating the development of new products and systems. Programme participants have access to Nestlé's R&D expertise and its infrastructure, including labs, kitchens and pilot-scale equipment. 

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Joanne Collins +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Sara Welford +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAPPUACBUPPUMQ
Date   Source Headline
4th Jun 20265:59 pmRNS-RAgronomics portfolio company HydGene Update
4th Jun 20265:58 pmRNS-RAgronomics portfolio company Bond Pet Foods Update
18th May 20267:00 amRNSNet Asset Value calculation as at 31 March 2026
12th May 20267:00 amRNSAgronomics leads US$5m investment in SuperMeat
7th May 20264:04 pmRNSMeatly completes £10.4 million Series A funding
15th Apr 20261:29 pmRNS-RClean Food Group Update
14th Apr 20267:00 amRNS-RTropic’s product receives regulatory approval
1st Apr 202612:50 pmRNS-RAll G secures FDA "no questions" letter
25th Mar 20263:45 pmRNS-RClean Food Group Update
19th Mar 202612:30 pmRNS-RTropic Biosciences Update
12th Mar 20265:31 pmRNSDirector's Dealing
4th Mar 20267:00 amRNSDirector’s Dealing
25th Feb 20265:04 pmRNSDirector’s Dealing
20th Feb 20265:15 pmRNSDirector’s Dealing
19th Feb 20262:10 pmRNSDirector’s Dealing
17th Feb 20267:00 amRNSHalf-year Financial Report
13th Feb 20264:31 pmRNSResult of AGM
9th Feb 20267:00 amRNSNet Asset Value calculation as at 31 December 2025
15th Jan 20267:00 amRNSAgronomics invests A$3m in All G & Issue of Equity
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20258:00 amRNSFinal Results and Notice of AGM
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
30th Dec 20257:00 amRNSFurther equity investment in BlueNalu
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSDissolution of Meatable
19th Dec 20259:30 amRNSLiberation Bioindustries Series A1 equity round
21st Nov 20258:00 amRNSAgronomics invests US$ 2 million in SuperMeat
13th Nov 20257:00 amRNSNet Asset Value as at 30 September 2025
10th Nov 20257:00 amRNS-REVERY raise US$ 55 million in fresh capital
21st Oct 20257:00 amRNS-RGeltor, Inc Update
30th Sep 20257:00 amRNS-RClean Food Group Update
23rd Sep 20257:00 amRNS-ROnego Bio Update
12th Sep 20258:00 amRNS-RClean Food Group Update
22nd Aug 20258:19 amRNS-RMeatable acquires Meat Technology platform
24th Jul 20257:00 amRNS-RSolar Foods Update
18th Jul 202511:00 amRNSNet Asset Value calculation as at 30 June 2025
11th Jun 20257:00 amRNS-RAgronomics Q2 2025 Newsletter
28th May 20252:55 pmRNS-RMeatly reduces bioreactor and medium costs
12th May 20257:00 amRNSNet Asset Value calculation as at 31 March 2025
8th May 20257:00 amRNS-RLiberation Labs Announce Manufacturing Partnership
6th May 20257:00 amRNS-RMeatable and TruMeat Forge Alliance
30th Apr 20257:00 amRNS-RBlueNalu Expands Partnership with Nomad Foods
15th Apr 20259:00 amRNS-RLiberation Labs secures strategic partnership
18th Mar 20257:00 amRNSExercise of Shellbay options
14th Mar 20258:15 amRNSUnaudited Interim Results
4th Mar 20258:00 amRNS-RSolar Foods Secures €10 million Grant
7th Feb 20253:33 pmRNSResult of AGM
7th Feb 20257:00 amRNS-RMeatly launches first cultivated meat dog treat
4th Feb 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.